STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling

NCT01368003 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Loss of funding.

Conditions

Adenocarcinoma of the Prostate

Interventions

DRUG: STA9090
DRUG: STA9090 with Dutasteride

Sponsor

Toni Choueiri, MD